Completed PHASE1 INTERVENTIONAL 2-arm NCT00513968

Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine

A Single Center, Randomized, Open-label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-week Period

Sponsor: Genexine, Inc.

Conditions Chronic Hepatitis B

Interventions Adefovir a mixed plasmid DNA (HB-110)

Updated 6 times since 2017 Last updated: Aug 3, 2012 Started: Jul 31, 2007 Primary completion: Apr 30, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00513968, this PHASE1 trial focuses on Chronic Hepatitis B and remains completed. Sponsored by Genexine, Inc., it has been updated 6 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genexine, Inc.

Data source: Genexine, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea